参麦注射液联合TP方案治疗晚期卵巢癌疗效观察  

Effects of Shenmai Injection Combined with TP Regimen on the Treatment of Advanced Ovarian Cancer

作　　者：郝颂华[1,2] 杨玲竹[1] 王欣[3] 

机构地区：[1]郑州大学第一附属医院妇产科,河南郑州450052 [2]河南电力医院妇产科,河南郑州450052 [3]河南省食品药品检验所,河南郑州450003

出　　处：《肿瘤基础与临床》2010年第4期315-316,共2页journal of basic and clinical oncology

摘　　要：目的探讨参麦注射液联合TP方案治疗晚期卵巢癌的疗效、毒副反应及其对免疫功能的影响。方法 60例晚期卵巢癌随机分为参麦组和对照组。参麦组30例在采用TP方案化疗的基础上加用参麦注射液;对照组30例单用TP方案化疗。观察两组的临床疗效和毒副反应及治疗前后T淋巴细胞亚群的变化。结果参麦组有效率为56.7%,高于对照组的50.0%,差异无统计学意义(P>0.05)。对照组治疗后T淋巴细胞亚群明显下降(P<0.05),参麦组治疗前后T淋巴细胞无明显改变(P>0.05);治疗后参麦组T淋巴细胞亚群高于对照组(P<0.05)。参麦组毒副反应明显低于对照组(P<0.05)。结论参麦注射液联合TP方案化疗治疗晚期卵巢癌,疗效显著,并降低了化疗的毒副反应及其对免疫功能的影响。Objective To investigate the curative effect and toxicities of shenmai injection plus TP regimen for advanced ovarian cancer,and observe the changes of immunologic function.Methods Sixty patients were randomly divided into two groups.The patients in the shenmai group were given TP regimen and shenmai injection.The patients in the control group received TP regimen.The curative effect and toxicities were observed.Before and after the treatment,T-cell subpopulation was observed too.Results The response rate in the shenmai group was 56.7%,and the control group was 50.0%（P 0.05）.After the treatment,the T-cell subpopulation in the shenmai group had no marked change（P 0.05）,that of the control group had significant descent（P 0.05） ;and that of the shenmai group was higher than the control group（P 0.05）.The toxicities of the shenmai group was lower than the control group（P 0.05）.Conclusion Shenmai injection combined with TP regimen is effective in the treatment of patients with advanced ovarian cancer.Shenmai injection can reduce the toxicities of chemotherapy and the effect of chemotherapy on immunologic function.

关 键 词：卵巢癌 参麦注射液 紫杉醇 顺铂 

分 类 号：R737.31[医药卫生—肿瘤]